Cover: Subscription Models for Prescription Drugs

Subscription Models for Prescription Drugs

The Motivation, Potential, and Limitations of a New Payment Model

Published May 21, 2020

by Harry H. Liu, Andrew W. Mulcahy, Adam J. Rose

Download Free Electronic Document

FormatFile SizeNotes
PDF file 0.2 MB

Use Adobe Acrobat Reader version 10 or higher for the best experience.

Some new prescription drugs—for example, the new generation of hepatitis C drugs initiated by introduction of Sovaldi and Harvoni—offer substantial improvements in health outcomes and reductions in future health care spending. However, new drugs offering significant benefits may have a large demand and thus the potential to strain the budgets of state Medicaid programs and other public payers, reserves of private payers, and resources of patients who pay out of pocket. Medicaid programs in Louisiana and Washington and federal programs in Australia have turned to a subscription model—instead of the more traditional negotiation of a per-unit price—as a way to pay for hepatitis C drugs.

It remains unclear whether the potential benefits of subscription models are specific to hepatitis C drugs for public payers or have broader potential. In this Perspective, the authors argue that, conceptually, the main advantage of subscription models over traditional prescription drug payment arrangements is that they could reduce some sources of uncertainty in spending for payers and in revenue for manufacturers. But compared with traditional prescription drug payment arrangements, the ability of subscription models to lower prescription drug spending is limited. Reducing uncertainty does not seem to have been the main driver of Louisiana's and Washington's use of a subscription model to purchase hepatitis C drugs. Instead, these states appear to have turned to subscription models to circumvent barriers to price negotiation imposed by the Medicaid Drug Rebate Program.

Research conducted by

This research was funded by Amgen Inc. and carried out within the Payment, Cost, and Coverage Program in RAND Health Care.

This commentary is part of the RAND expert insight series. RAND Expert Insights present perspectives on timely policy issues. All RAND Expert Insights undergo peer review to ensure high standards for quality and objectivity.

This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit

RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.